Acclinate, a company mobilizing diverse communities for improved healthcare access, has announced the successful closure of its $7 million Series A financing round. Led by Cencora Ventures, with participation from Labcorp and Latimer Ventures, this funding will support Acclinate’s efforts to expand its impact in the realm of clinical trial diversity and health equity.
“This investment represents a pivotal moment for Acclinate and underscores our unwavering commitment to reshaping health equity and fostering diversity in clinical trials on a larger scale,” stated Del Smith, CEO, and Co-Founder of Acclinate. “With the support of esteemed healthcare organizations like Cencora and Labcorp, we are well-positioned to drive tangible change in the healthcare landscape and empower diverse communities to take charge of their health proactively.”
Acclinate is dedicated to enhancing diversity in clinical trials through its innovative community engagement platform, which has gained the trust of leading pharmaceutical clients. The platform aids in making existing trials more inclusive and designing more diverse studies for the future.
The fresh funds will fuel Acclinate’s expansion efforts and further enhance its powerful Enhanced Diversity in Clinical Trials (e-DICT) platform.
